Former high-flying I/O biotech shelves lead drugs, chops staff and hands off the remnants in Nasdaq reshuffle

If there’s one lesson that shines through in the retrenchment going on now in biotech, it’s that no great startup story — regardless of its distinguished …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

Former high-flying I/O biotech shelves lead drugs, chops staff and hands off the remnants in Nasdaq reshuffle

This article is available only to Premium subscribers

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Corvus' early-phase atopic dermatitis data prompt stock rally

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

GSK awaits Nucala decision after FDA target date passes

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

For­mer high-fly­ing I/O biotech shelves lead drugs, chops staff and hands off the rem­nants in Nas­daq reshuf­fle

This article is available only to Premium subscribers

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

AI biotech In­sil­i­co Med­i­cine goes for third at­tempt at Hong Kong IPO

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

Former high-flying I/O biotech shelves lead drugs, chops staff and hands off the remnants in Nasdaq reshuffle

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Corvus' early-phase atopic dermatitis data prompt stock rally

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

GSK awaits Nucala decision after FDA target date passes

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges